Performance of BCRAT in high-risk patients with breast cancer
- PMID: 31162092
- PMCID: PMC7927660
- DOI: 10.1016/S1470-2045(19)30301-8
Performance of BCRAT in high-risk patients with breast cancer
Conflict of interest statement
I declare no competing interests.
Comment in
-
Performance of BCRAT in high-risk patients with breast cancer - Authors' reply.Lancet Oncol. 2019 Jun;20(6):e286. doi: 10.1016/S1470-2045(19)30311-0. Lancet Oncol. 2019. PMID: 31162093 No abstract available.
Comment on
-
10-year performance of four models of breast cancer risk: a validation study.Lancet Oncol. 2019 Apr;20(4):504-517. doi: 10.1016/S1470-2045(18)30902-1. Epub 2019 Feb 21. Lancet Oncol. 2019. PMID: 30799262
References
-
- Terry MB, Liao Y, Whittemore AS, et al. 10-year performance of four models of breast cancer risk: a validation study. Lancet Oncol 2019; 20: 504–17. - PubMed
-
- National Cancer Institute. Surveillance, Epidemiology, and End Results Program. SEER*Explorer. Breast cancer SEER incidence rates by age at diagnosis, 2011–2-15 by race/ ethnicity. https://seer.cancer.gov/explorer/application.php?site=55&data_type=1&gra... (accessed April 1, 2019).
-
- Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA. Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 2001; 93: 358–66. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
